STAMPEDE试验:高危局部或转移性前列腺癌长期激素治疗的心血管事件
该事后分析纳入STAMPEDE试验中6292例接受ADT为基础治疗的前列腺癌患者,评估ARPI等强化治疗的心血管安全性及SCORE2表现。ARPI强化未显著增加MACE风险,SCORE2区分度中等且低估绝对风险。
要点
- ARPI强化5年MACE累积发生率M0为9%、M1为7%,与ADT单药相当。
- AAP、AAP+ENZ、DOC、ZA或放疗均未显著增加MACE风险。
- 心血管病史是MACE最强预测因素,SCORE2低估风险。
核心结论
- 与ADT单药相比,ARPIs、DOC、ZA或前列腺放疗未观察到MACE的统计学显著增加。
- SCORE2低估心血管风险,支持开发前列腺癌特异性心血管风险模型。
研究设计与样本
- STAMPEDE试验事后分析,纳入6292例接受AAP、AAP+ENZ、DOC、ZA或RT比较的患者,并链接英格兰医疗记录。
- 采用灵活参数竞争风险模型估计累积发生率和亚分布风险比(SDHR),并评估SCORE2区分度与校准度。
主要发现
- ARPI强化5年MACE累积发生率:非转移(M0)疾病9%,转移(M1)疾病7%,与ADT单药相当。
- AAP:M0 SDHR 1.15(95%CI 0.80-1.67),M1 SDHR 1.36(95%CI 0.87-2.10)。
- AAP+ENZ:M0 SDHR 1.34(95%CI 0.91-1.98),M1 SDHR 1.28(95%CI 0.85-1.94)。
- 心血管病史是MACE最强预测因素。
- 5076例符合SCORE2评估,4239例有完整基线数据;SCORE2区分度中等(10年AUC M0 0.63,M1 0.61),绝对心血管风险被低估。
关键数值与推荐
- MACE通过预设的ICD-10和OPCS-4编码识别。
- SCORE2评估:10年AUC M0为0.63、M1为0.61,绝对风险被低估。
临床怎么用
- 对于接受长期激素治疗的高危局部或转移性前列腺癌患者,ARPI等强化治疗未显示显著增加MACE风险。
- 临床可参考心血管病史评估MACE风险,但SCORE2可能低估风险,需谨慎解读。
局限性
- 严重心血管合并症患者代表性不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major adverse cardiovascular events (MACE) are a leading cause of noncancer death in men with prostate cancer (PCa). Androgen receptor pathway inhibitors (ARPIs) improve oncologic outcomes but may exacerbate cardiovascular risk. The Systematic Coronary Risk Evaluation 2(SCORE2) estimates 10-yr cardiovascular risk, yet its validity in men receiving treatment for PCa is untested. OBJECTIVE: To evaluate the cardiovascular safety of ARPIs and other treatment intensification strategies within the STAMPEDE trial and assess SCORE2 performance. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis included patients allocated to the abiraterone acetate plus prednisolone (AAP), AAP plus enzalutamide (ENZ), docetaxel (DOC), zoledronic acid (ZA), and radiotherapy (RT) comparisons in STAMPEDE with linked health care records in England. INTERVENTION: Treatment intensification with AAP, AAP plus ENZ, DOC, ZA, or prostate RT in addition to standard-of-care androgen deprivation therapy (ADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: MACE were identified using prespecified International Classification of Diseases, 10th Revision, and Office of Population Censuses and Surveys Classification of Interventions and Procedures codes. Flexible parametric competing-risk models estimated cumulative incidence and subdistribution hazard ratios (SDHRs). SCORE2 discrimination and calibration were evaluated. RESULTS AND LIMITATIONS: A total of 6292 men were included. The 5-yr cumulative MACE incidence with ARPI intensification was 9% in nonmetastatic (M0) disease and 7% in metastatic (M1) disease, comparable to ADT alone. ARPI intensification was not associated with a statistically significant increase in MACE risk (AAP: M0 SDHR 1.15 [95% confidence interval {CI} 0.80-1.67], M1 SDHR 1.36 [95% CI 0.87-2.10]; AAP plus ENZ: M0 SDHR 1.34 [95% CI 0.91-1.98], M1 SDHR 1.28 [95% CI 0.85-1.94]). Cardiovascular disease history was the strongest predictor of MACE. Among 5076 patients eligible for SCORE2 assessment, 4239 had complete baseline data. SCORE2 discrimination was modest (10-yr area under the curve 0.63 for M0 disease and 0.61 for M1 disease), and absolute cardiovascular risk was underestimated. Limitations included underrepresentation of patients with severe cardiovascular comorbidity. CONCLUSIONS: No statistically significant increase in MACE was observed with ARPIs, DOC, ZA, or prostate RT compared with ADT alone. SCORE2 underestimated cardiovascular risk, supporting development of PCa-specific cardiovascular risk models.
引用
- El-Taji O, Dutey-Magni P, Brown M, et al. Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial. Eur Urol. 2026. PMID: 42838799. doi:10.1016/j.eururo.2026.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。